Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms

Postgraduate Medicine
Ho-Jun SeoChi-Un Pae

Abstract

Desvenlafaxine succinate (DVS) is one of several serotonin-norepinephrine reuptake inhibitors (SNRIs). Others are venlafaxine hydrochloride, milnacipran, and duloxetine. Desvenlafaxine has been approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) based on a number of randomized, placebo-controlled clinical trials. Clinical studies have investigated the efficacy of DVS in doses ranging from 50 to 400 mg/day for the treatment of MDD in adult outpatients. The effects of DVS 50 mg/day have been clearly distinguished from placebo in the reduction of MDD symptoms in such clinical trials. No additional therapeutic benefits were found at doses > 50 mg/day. The recommended dose of DVS ranges from 50 to 100 mg. Desvenlafaxine is currently the third SNRI approved by the FDA for this indication. Preliminary evidence also suggests the clinical usefulness of DVS in the treatment of vasomotor symptoms of menopause, anxiety symptoms, and painful physical symptoms. The modified pharmacokinetic and pharmacodynamic profiles of DVS differentiate this drug from the original product, venlafaxine. Significant points of difference, compared with venlafaxine, are once-daily dosing and the achievemen...Continue Reading

References

Nov 7, 2000·Maturitas·H H Berendsen
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Jun 5, 2003·JAMA : the Journal of the American Medical Association·Vered StearnsEric Dube
Jun 19, 2003·JAMA : the Journal of the American Medical Association·Ronald C KesslerUNKNOWN National Comorbidity Survey Replication
Sep 21, 2004·Human Psychopharmacology·Olivier VittonSrinivas G Rao
Dec 31, 2004·Obstetrics and Gynecology·Michele L EvansRobert B Jaffe
Jan 5, 2006·The American Journal of Psychiatry·Madhukar H TrivediUNKNOWN STAR*D Study Team
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Michael H Ossipov, Frank Porreca
May 6, 2006·The Journal of Pharmacology and Experimental Therapeutics·Darlene C DeecherTerrance H Andree
Aug 1, 2006·International Clinical Psychopharmacology·John CooksonDaniel K Kajdasz
Jun 15, 2007·Expert Review of Neurotherapeutics·Chi-Un PaeAshwin A Patkar
Aug 4, 2007·The Journal of Pharmacology and Experimental Therapeutics·John N MasonRandy D Blakely
Oct 6, 2007·International Clinical Psychopharmacology·Lucia Septien-VelezKaren A Tourian
Jan 4, 2008·The New England Journal of Medicine·R H Belmaker, Galila Agam
Mar 29, 2008·Menopause : the Journal of the North American Menopause Society·Kathleen W WyrwichJoel D Bobula
May 30, 2008·Current Medical Research and Opinion·Michael R LiebowitzKaren A Tourian
Jun 12, 2008·International Clinical Psychopharmacology·Daniel Z LiebermanBruno Pitrosky
Sep 24, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Albena PatronevaAlice I Nichols
Dec 6, 2008·Journal of Psychiatric Practice·Sheldon H PreskornChristine J Guico-Pabia
Dec 18, 2008·Expert Review of Neurotherapeutics·Jayesh Kamath, Venkatesh Handratta
Jan 27, 2009·American Journal of Obstetrics and Gynecology·David F ArcherUNKNOWN Study 319 Investigators

❮ Previous
Next ❯

Citations

Dec 16, 2010·CNS Neuroscience & Therapeutics·Bernardo Dell'OssoA Carlo Altamura
Aug 25, 2015·The Cochrane Database of Systematic Reviews·Helen C GallagherMartin C Henman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.